The Ohio state University Medical Center
Columbus, Ohio, 43210, United States
NCT Number: NCT01578629
A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I & IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol.
Looking for future studies?
Notify Me40 year–70 year
All sexes
Interventional
Phase 1 / Phase 2
Columbus, Ohio, 43210, United States
A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I & IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol. Phase I subjects will be healthy volunteers, recruited by an advertisement. Phase IIA subjects will be hyperlipidemic (having high cholesterol), and will be referred to us by their Wound Care Center Physicians. Patients will be randomized to receive placebo pills, (400 or 800 mg) TCT pills, low-dose 81 mg aspirin (commonly used for secondary prevention of stroke), or TCT and aspirin together. Potential subjects for Phase-I who meet study criteria and agree to participate will be in the study for 6 months and have the following study related procedures, blood draw total 4 times, tape stripping (non-invasive procedure), BMI, and blood pressure measurement at each visit (every month). Participants in Phase-IIA will have blood drawn a total of 6 times, tape stripping, BMI and blood pressure measurement and participants will be in the study for 13 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Phase IA
Inclusion criteria
Exclusion criteria
- (as self reported by potential participants during review of eligibility criteria with Research Nurse,)
Phase IIA
Inclusion criteria
Exclusion criteria
Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
vehicle control compared to Vitamin E TCT pills
Other names: placebo capsule
Time frame: up to one year
Blood draw followed by platelet aggregometry
Time frame: up to one year
blood lipid panel including HDL, LDL, total cholesterol
Time frame: up to one year
HPLC vitamin E analysis of tape strips for compliance
Andrew Slivka
Other
Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA
Acronym: NUTRITION
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01804439
Abdominal Aortic Aneurysm, Acute Myocardial Infarction
View Trial DetailsNCT02900521
Brain Diseases, Brain Hemorrhage
Brest, France
View Trial DetailsNCT04611893
Brain Diseases, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT01387113
Brain Diseases, Cardiovascular Diseases
San Francisco, California, United States
View Trial Details